Vascular endothelial growth factor A (VEGFA) (VEGFA)

Vascular endothelial growth factor A (VEGFA) is a critical signaling protein that regulates both physiological and pathological angiogenesis and vasculogenesis [2, 3]. It belongs to the cystine-knot growth factor family and exerts its effects primarily by binding to the tyrosine kinase receptors VEGFR1 and VEGFR2 on endothelial cells, leading to cell proliferation, migration, and increased vascular permeability [1, 10]. In many cancers, VEGFA is overexpressed to facilitate the development of a tumor-associated blood supply, which is essential for tumor growth and metastasis [4, 6]. Beyond oncology, VEGFA plays a significant role in ocular diseases characterized by neovascularization, such as age-related macular degeneration [1, 3]. JS207 is a recombinant humanized bispecific antibody designed to target both VEGFA and the immune checkpoint receptor PD-1 [1, 2]. By neutralizing VEGFA, JS207 inhibits tumor angiogenesis and normalizes the tumor microenvironment, which can enhance the infiltration of immune cells [5, 12]. Simultaneously, its anti-PD-1 component blocks the inhibitory signaling between T cells and tumor cells, reactivating the immune system's ability to recognize and destroy cancer [2, 11]. This dual-targeting strategy is intended to provide synergistic therapeutic effects and overcome resistance mechanisms associated with single-agent therapies [3, 8].

Other names

VEGFVEGF-AVascular permeability factorVPF

JS207 is a bispecific antibody that simultaneously binds to VEGFA and PD-1. It inhibits VEGFA-mediated signaling through VEGFR1 and VEGFR2 to suppress angiogenesis and vascular permeability, while also blocking the PD-1/PD-L1 pathway to restore T-cell mediated anti-tumor immunity.